Fujirebio � Biomarker development for Alzheimer's Disease

Fujirebio was established in 1950 and specializes in the development diagnostic biomarkers for identifying metabolic,  neurodegenerative, and infectious diseases as well as cancer.  Fujirebio is currently recruiting for a clinical trial (NCT03174938) that will evaluate the safety and efficacy of a diagnostic biomarker it has developed for detecting Alzheimer’s disease in blood.